Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_205_библиотеки_им_акад_М_И_Перельмана

Following FDA clearance of the Neuronetics device and its early uptake by clinical practices, a large multisite naturalistic treatment study confirmed similar efficacy for patients with MDD who were treated outside of research protocols with the device (Carpenter et al. 2012). This study reflected “real-life” TMS clinical practice, where most patients are taking one or more antidepressant or other psychotropic medica tions at the time of referral and remain on concurrent medication during the TMS treatment course. Outcomes for 307 patients (whose treatment costs were supported by their health insurance or through self-pay) across 42 clinics demonstrated that about half (42%–58%, depending on which scale is used) of patients were responders (defined by at least 50% improvement from baseline) and approximately one-third reached the threshold scores for remission (27%–37% across three measures). These findings were largely consistent with other open-label data, such as the crossover phase in the Neuronetics regulatory trial (Avery et al. 2008).